OakChart

Alzamend Neuro Inc

ALZNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.31-0.04 (-2.96%)
2026-11-12 03:15 CET
Market cap
6.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-9.10 USD m
Free cash flow, TTM
-6.84 USD m
EPS diluted, TTM
-2.29
P/E
-
Compare

Price

ALZN against its 20, 50 and 200-day averages
2050200earnings
1.001.251.501.752.001.2M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALZNclose 1.3120-day 1.2950-day 1.50200-day 1.441.31

48.8% under the 52-week high of 2.56 on 19 Nov 2025. 52-week low 0.84 on 13 Apr 2026. Last 15 sessions, 50.9% high to low

Volume 0.19× normal · the line is the 50-bar volume average

Profile

ALZN
52-week range, 27% of the way up
0.842.56

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Employees6
IPOJun 15, 2021
Beta0.40
ATR, 14d0.14
Rel volume0.19
Short float0.37%
Insider own2.66%
Inst own24.49%

Snapshot

6 groups

Valuation

Index-
Market Cap6.32M
Enterprise Value-1.27M
Income-9.10M
Sales0.00M
Book/sh1.20
Cash/sh1.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOJun 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.09
P/C0.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.01
Current Ratio3.01
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.29
EPS next Y-0.87
EPS next Q-0.23
EPS this Y60.08%
EPS next Y17.14%
EPS next 5Y-
EPS past 3/5Y76.63% 51.15%
Sales past 3/5Y- -
EPS Y/Y TTM73.61%
Sales Y/Y TTM-
EPS Q/Q47.33%
Sales Q/Q-
EarningsSep 15
EPS/Sales Surpr.0.00% -

Ownership

Insider Own2.66%
Insider Trans-1.53%
Inst Own24.49%
Inst Trans-5.18%
ROA-122.36%
ROE-163.23%
ROIC-156.77%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.24%
SMA50-12.77%
SMA200-9.07%
Trades-

Technical

Shs Outstand4.83M
Shs Float4.70M
Short Float0.37%
Short Ratio0.21
Short Interest0.02M
52W High2.56 -48.83%
52W Low0.84 55.95%
Volatility13.32% 10.43%
ATR (14)0.14
RSI (14)45.78
Beta0.40
Rel Volume0.19
Avg Volume81.92K
Volume15,936

Performance

Perf Week-14.38%
Perf Month-2.96%
Perf Quarter-10.27%
Perf Half Y25.96%
Perf YTD-28.02%
Perf Year-44.49%
Perf 3Y-99.00%
Perf 5Y-99.96%
Perf 10Y-
Recom1.00
Target Price26.00
Prev Close1.35
Price1.31
Change %-2.96%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 01, 2021InitiatedAAscendiant Capital MarketsBuy$8+510.7%

Peers

Mkt cap
TickerCompanyMkt cap
ANVSAnnovis Bio Inc36.41M
BIVIBioVie Inc13.51M
AVXLAnavex Life Sciences Corp98.26M
CGTXCognition Therapeutics Inc64.42M
ACOGAlpha Cognition Inc187.72M
ABOSAcumen Pharmaceuticals Inc16.64M
CRVOCervoMed Inc26.78M
INMBINmune Bio Inc34.05M
PMNProMIS Neurosciences Inc33.72M
ATHEAlterity Therapeutics Ltd ADR44.12M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
AULT MILTON C IIIDirectorAug 26 '26Sale1.562,0003,1160Aug 31 06:05 AM
AULT MILTON C IIIDirectorApr 14 '26Buy1.00108,388108,897116,648Apr 16 04:30 PM
AULT MILTON C IIIDirectorDec 23 '25Sale2.071,8513,8250Dec 30 05:54 PM
Horne William B.DirectorDec 19 '25Sale2.123,3337,0590Dec 23 04:30 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC (PR Newswire) +7.24%
  • Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain (PR Newswire)
  • Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending (PR Newswire) +8.21%
  • Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital (PR Newswire)
  • Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions (PR Newswire) -22.28%
  • Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital (PR Newswire)
  • Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
  • Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
  • EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks) -14.72%
  • Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital (PR Newswire) -5.33%
  • EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants (Benzinga)
  • Alzamend Neuro to Present at the 2025 Military Health System Research Symposium (GlobeNewswire) -6.42%
  • Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs (GlobeNewswire) -5.94%
  • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-09-15-0.560-0.560-3.5100.000.001
2025Q42026-07-01-0.720-0.670-0.7380.000.001
2025Q32026-03-19-0.580-0.530-0.5780.000.001
2025Q22025-12-31-0.300-0.300-0.2960.000.001
2025Q12025-09-16-1.280-2.080-1.2830.000.002
2024Q42025-07-02-2.360-2.700-2.2210.000.001
2024Q32025-03-13-1.710-3.195-1.6950.000.002
2024Q22025-01-01-3.555-3.600-3.4700.000.001
2024Q12024-09-10-11.250-21.420-11.2750.000.001
2023Q42024-07-03-10.890-34.200-11.1390.000.001
2023Q32024-03-14-34.200-29.250-33.9680.000.002
2023Q22024-01-03-39.600-46.800-39.8470.000.002
2023Q12023-09-12-51.300-54.000-48.3840.000.001
2022Q42023-06-28-40.500-60.750-46.1700.000.002
2022Q32023-03-16-81.000-54.000-74.4930.000.001
2022Q22022-12-12-40.500--43.0650.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-94.500--94.5000.00-
2021FY-189-168.75-187.310.000.00
2022FY-202.5-216-205.970.000.00
2023FY-132.3-155.7-132.330.000.00
2024FY-10.670-11.880-10.0200.000.00
2025FY-2.630-2.580-10.0200.000.00
2026FY--1.050--0.00
2027FY--0.870--0.00
2028FY--0.860--32.19
2029FY-6.990--136.03

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-09-151000.000.000.00
2026Q2S2026-07-011000.000.000.00
2026Q2S2026-03-191000.000.000.00
2026Q2S2025-12-311000.000.000.00
2026Q2S2025-11-111000.000.000.00
2026Q2S2025-11-101000.000.000.00
2026Q2S2025-11-091000.000.000.00
2026Q2S2025-11-081000.000.000.00
2026Q2S2025-11-071000.000.000.00
2026Q2S2025-11-061000.000.000.00
2026Q2S2025-11-051000.000.000.00
2026Q2S2025-11-041000.000.000.00
2026Q2S2025-11-031000.000.000.00
2026Q2S2025-11-021000.000.000.00

Estimate history

EPS, annual-14.742-76.95-69.795-94.5-187.313-205.97-132.33-11.325-2.629-2.288
Period201720182019202020212022202320242025TTM
EPS, quarterly-11.275-3.47-1.695-2.221-1.283-0.296-0.578-0.738-0.676
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.0630.0630.0630.050.0710.0720.0760.7794.2564.826
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0960.5810.6440.7793.143.8023.8054.2564.826
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.110.110.050.050.020.000.000.000.00
Gross Profit-0.11-0.11-0.05-0.05-0.020.000.000.000.00
Selling, General and Administrative Excl. Other8.988.664.459.8914.8512.324.954.425.01
Research and Development2.973.631.416.467.455.201.311.073.70
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.09-8.77-4.50-9.94-14.87-12.32-4.95-4.42-5.01
Interest Expense0.000.010.020.010.010.050.160.000.00
Unusual Expense0.000.000.000.000.00-0.00-0.060.000.00
Net Income Before Taxes-9.10-8.77-4.51-9.95-14.88-12.36-5.05-4.41-4.86
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-9.10-8.77-4.51-9.95-14.88-12.36-5.05-4.41-4.86
Net Income From Continuing Operations-9.10-8.77-4.51-9.95-14.88-12.36-5.05-4.41-4.86
Net Income-9.10-8.77-5.11-9.95-14.88-12.36-5.05-4.41-4.86
EPS (Recurring)-2.03-2.63-11.32-132.33-205.97-187.36-94.59-69.79-76.95
EPS (Basic, Before Extraordinaries)-2.29-2.63-11.32-132.33-205.97-187.31-94.50-69.80-76.95
EPS (Diluted)-2.29-2.63-11.32-132.33-205.97-187.31-94.50-69.80-76.95
EBITDA-8.98-8.66-4.45-9.89-14.85-12.32-4.95-4.42-5.01
Non-Operating Income (Expense)-0.000.000.000.000.000.000.000.010.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.740.710.330.963.584.412.372.260.40
Shares Outstanding4.834.260.780.080.070.070.050.060.06
Market Capitalization6.326.324.634.8952.7791.9091.90--

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.030.010.010.01
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.01-0.01-0.01
Selling, General and Administrative Excl. Other3.002.842.170.972.671.131.021.35
Research and Development1.090.431.280.181.740.450.450.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.03-2.87-2.20-1.00-2.70-1.14-1.04-1.36
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.03-2.87-2.20-1.00-2.70-1.14-1.04-1.36
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.03-2.87-2.20-1.00-2.70-1.14-1.04-1.36
Net Income From Continuing Operations-3.03-2.87-2.20-1.00-2.70-1.14-1.04-1.36
Net Income-3.03-2.87-2.20-1.00-2.70-1.73-1.04-1.36
EPS (Recurring)-0.68-0.74-0.58-0.30-1.28-2.22-1.70-3.47
EPS (Basic, Before Extraordinaries)-0.68-0.74-0.58-0.30-1.28-2.22-1.70-3.47
EPS (Diluted)-0.68-0.74-0.58-0.30-1.28-2.22-1.70-3.47
EBITDA-3.00-2.84-2.17-0.97-2.67-1.13-1.02-1.35
Non-Operating Income (Expense)0.000.00-0.00-0.00-0.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.080.620.010.030.040.080.080.08
Shares Outstanding4.834.263.803.803.140.780.640.58
Market Capitalization6.324.348.177.946.524.636.588.21

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments0.713.950.385.1414.061.930.090.040.55
Short Term Receivables0.000.000.000.000.000.020.190.290.42
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.050.230.080.690.350.611.531.171.45
Total Current Assets1.764.180.465.8414.412.561.811.502.42
Net Property, Plant & Equipment0.310.430.180.080.100.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.350.000.000.00
Total Assets2.084.600.635.9214.522.911.811.502.42
Short Term Debt Incl. Current Port. of LT Debt0.000.000.300.000.000.340.000.000.00
Accounts Payable1.350.630.000.000.000.000.000.000.00
Other Current Liabilities0.000.002.932.871.160.560.991.180.10
Total Current Liabilities1.350.633.232.871.160.900.991.180.10
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities1.350.633.232.871.160.900.991.180.10
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity0.733.97-2.593.0513.352.010.820.322.32
Total Shareholders Equity0.733.97-2.593.0513.352.010.820.322.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity0.733.97-2.593.0513.352.010.820.322.32
Total Liabilities & Stockholders Equity2.084.600.635.9214.522.911.811.502.42
Book Value Per Share0.175.10-33.9442.41188.7740.3013.005.0136.70
Tangible Book Value Per Share0.175.10-33.9442.41188.7740.3013.005.0136.70
Full-Time Employees677442433
Price to Book Ratio1.091.17-1.899.017.687.68---
Return on Assets-262.55-172.50-303.88-145.64-141.86-213.54-266.08-248.28-
Return on Equity-373.18-657.17-4,408.31-181.47-160.92-356.06-774.66-368.90-
Return on Invested Capital-1,196.43-113.78--488.53-92.59-250.71-536.72-1,534.32-40.17
Quick Ratio1.316.580.142.0312.372.851.831.2724.98
Current Ratio1.316.580.142.0312.372.851.831.2724.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-9.10-8.77-4.51-9.95-14.88-12.36-5.05-4.41-4.86
Depreciation0.110.110.050.050.02----
Other Funds (Non Cash)0.740.710.330.963.584.422.492.262.59
Funds from Operations-8.24-7.95-4.13-8.94-11.27-7.94-2.56-2.15-2.28
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.40-0.11-2.440.672.351.33-0.15-0.191.23
Cash from Operating Activities-6.84-8.07-6.57-8.27-8.92-6.61-2.71-2.35-1.05
Capital Expenditures0.000.00-0.30-0.150.00-0.110.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00-0.56
Other Sources0.000.000.000.000.000.000.100.100.79
Cash from Investing Activities0.000.00-0.30-0.150.00-0.110.100.100.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.814.8310.443.350.0018.912.102.290.24
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.814.8310.443.350.0018.912.102.290.24
Proceedsfrom Stock Options8.814.8310.443.350.0018.912.102.290.24
Issuance or Reduction of Debt, Net0.000.000.000.300.00-0.060.500.020.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.001.85-0.020.07
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.020.00
Cash from Financing Activities8.814.8310.443.650.0018.854.452.290.31
Net Change in Cash1.97-3.243.57-4.76-8.9212.131.840.05-0.50
Free Cash Flow-6.84-8.07-6.87-8.42-8.92-6.72-2.71-2.35-1.05
Preferred Dividends (Cash Flow)-0.00-0.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments7.590.712.714.455.623.95
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.661.050.990.270.310.23
Total Current Assets8.251.763.704.725.934.18
Net Property, Plant & Equipment0.290.310.340.370.400.43
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets8.542.084.045.096.334.60
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable2.741.351.860.720.980.63
Other Current Liabilities0.000.000.000.000.000.00
Total Current Liabilities2.741.351.860.720.980.63
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.741.351.860.720.980.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.800.732.184.375.343.97
Total Shareholders Equity5.800.732.184.375.343.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.800.732.184.375.343.97
Total Liabilities & Stockholders Equity8.542.084.045.096.334.60
Book Value Per Share1.200.170.571.151.705.10
Tangible Book Value Per Share1.200.170.571.151.705.10
Full-Time Employees666777
Price to Book Ratio1.091.991.871.490.441.17
Return on Assets-122.36-262.55-171.39-116.49-156.14-172.50
Return on Equity-163.23-373.18-249.97-144.76-302.25-657.17
Return on Invested Capital-52.17-391.42-100.66-22.88-50.58-28.71
Quick Ratio3.011.311.996.586.036.58
Current Ratio3.011.311.996.586.036.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-3.03-2.87-2.20-1.00-2.70-1.14
Depreciation0.030.030.030.030.030.01
Other Funds (Non Cash)0.080.620.010.030.040.08
Funds from Operations-2.92-2.22-2.16-0.94-2.63-1.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.78-0.580.43-0.230.270.36
Cash from Operating Activities-1.14-2.80-1.74-1.17-2.36-0.69
Capital Expenditures0.000.000.000.000.00-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.00-0.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.00-
Change in Capital Stock8.020.790.000.004.041.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.020.790.000.004.041.49
Proceedsfrom Stock Options8.020.790.000.004.041.49
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.020.790.000.004.041.49
Net Change in Cash6.88-2.00-1.74-1.171.670.59
Free Cash Flow-1.14-2.80-1.74-1.17-2.36-0.90

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.37%0.0M4.7M78.97K
2026-10-150.73%0.0M4.7M84.91K
2026-09-302.37%0.1M4.7M128.08K
2026-09-152.62%0.1M4.7M165.71K
2026-08-313.36%0.2M4.7M155.41K
2026-08-143.79%0.2M4.7M145.08K
2026-07-315.88%0.2M4.0M143.55K
2026-07-1510.29%0.3M3.2M146.61K
2026-06-304.94%0.2M3.2M111.08K
2026-06-153.93%0.1M3.2M130.77K
2026-05-294.67%0.1M3.2M131.93K
2026-05-156.26%0.2M3.2M130.51K
2026-04-306.42%0.2M3.2M137.75K
2026-04-157.79%0.2M3.2M149.79K
2026-03-318.79%0.3M3.7M142.30K
2026-03-136.63%0.2M3.7M73.89K
2026-02-277.27%0.3M3.7M73.35K
2026-02-137.10%0.3M3.7M84.29K
2026-01-304.70%0.2M3.7M83.38K
2026-01-154.79%0.2M3.7M85.17K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-K/A2026-08-03SEC
2026-10-09RWRegistration Withdrawal RequestSEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-314/A2026-04-14SEC
2026-08-314/A2026-04-14SEC
2026-08-28PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-19SEC
2026-08-21S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-204/A2026-07-31SEC
2026-08-203/A2026-07-29SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-043Initial statement of beneficial ownership of securities2026-07-29SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-045Annual statement of changes in beneficial ownership of securities2026-04-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-2210-KAnnual report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-07-218-KCurrent report2026-07-21SEC
2026-04-178-KCurrent report2026-04-17SEC
2026-04-164Statement of changes in beneficial ownership of securities2026-04-14SEC
2026-03-208-KCurrent report2026-03-20SEC
2026-03-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-03-06424B5SEC
2026-03-068-KCurrent report2026-03-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08003.12K1
2026-070000
2026-060000
2026-050000
2026-04108.90K100
2026-030000
2026-020000
2026-010000
2025-120010.88K2
2025-110000

Institutional holders

Manager% owned
Kingsbury Capital Investment Advisors LLC23.21%
VANGUARD FIDUCIARY TRUST CO0.55%
GEODE CAPITAL MANAGEMENT, LLC0.54%
VANGUARD CAPITAL MANAGEMENT LLC0.20%
Tower Research Capital LLC0.09%
UBS Group AG0.06%
BlackRock, Inc.0.01%
SBI Securities Co., Ltd.0.00%
IFG Advisory, LLC0.00%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.41%
VANGUARD EXTENDED MARKET INDEX FUND0.20%
Fidelity Series Total Market Index Fund0.10%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. ALZN. Cached 15 minutes.